170 related articles for article (PubMed ID: 23147415)
1. Mice heterozygous for AChE are more sensitive to AChE inhibitors but do not respond to BuChE inhibition.
Mohr F; Zimmermann M; Klein J
Neuropharmacology; 2013 Apr; 67():37-45. PubMed ID: 23147415
[TBL] [Abstract][Full Text] [Related]
2. Effects of acetylcholinesterase and butyrylcholinesterase inhibition on breathing in mice adapted or not to reduced acetylcholinesterase.
Boudinot E; Taysse L; Daulon S; Chatonnet A; Champagnat J; Foutz AS
Pharmacol Biochem Behav; 2005 Jan; 80(1):53-61. PubMed ID: 15652380
[TBL] [Abstract][Full Text] [Related]
3. Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity.
Hartmann J; Kiewert C; Duysen EG; Lockridge O; Greig NH; Klein J
J Neurochem; 2007 Mar; 100(5):1421-9. PubMed ID: 17212694
[TBL] [Abstract][Full Text] [Related]
4. Amino acid residues involved in stereoselective inhibition of cholinesterases with bambuterol.
Bosak A; Gazić I; Vinković V; Kovarik Z
Arch Biochem Biophys; 2008 Mar; 471(1):72-6. PubMed ID: 18167304
[TBL] [Abstract][Full Text] [Related]
5. 1,4-Substituted 4-(1H)-pyridylene-hydrazone-type inhibitors of AChE, BuChE, and amyloid-β aggregation crossing the blood-brain barrier.
Prinz M; Parlar S; Bayraktar G; Alptüzün V; Erciyas E; Fallarero A; Karlsson D; Vuorela P; Burek M; Förster C; Turunc E; Armagan G; Yalcin A; Schiller C; Leuner K; Krug M; Sotriffer CA; Holzgrabe U
Eur J Pharm Sci; 2013 Jul; 49(4):603-13. PubMed ID: 23643737
[TBL] [Abstract][Full Text] [Related]
6. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
7. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
8. Choline availability and acetylcholine synthesis in the hippocampus of acetylcholinesterase-deficient mice.
Hartmann J; Kiewert C; Duysen EG; Lockridge O; Klein J
Neurochem Int; 2008 May; 52(6):972-8. PubMed ID: 18023504
[TBL] [Abstract][Full Text] [Related]
9. Chimeric human cholinesterase. Identification of interaction sites responsible for recognition of acetyl- or butyrylcholinesterase-specific ligands.
Loewenstein Y; Gnatt A; Neville LF; Soreq H
J Mol Biol; 1993 Nov; 234(2):289-96. PubMed ID: 8230213
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
11. Screening of traditional European herbal medicines for acetylcholinesterase and butyrylcholinesterase inhibitory activity.
Wszelaki N; Kuciun A; Kiss AK
Acta Pharm; 2010 Mar; 60(1):119-28. PubMed ID: 20228046
[TBL] [Abstract][Full Text] [Related]
12. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
13. Amino acid residues involved in the interaction of acetylcholinesterase and butyrylcholinesterase with the carbamates Ro 02-0683 and bambuterol, and with terbutaline.
Kovarik Z; Radić Z; Grgas B; Skrinjarić-Spoljar M; Reiner E; Simeon-Rudolf V
Biochim Biophys Acta; 1999 Aug; 1433(1-2):261-71. PubMed ID: 10446376
[TBL] [Abstract][Full Text] [Related]
14. Butyrylcholinesterase and the control of synaptic responses in acetylcholinesterase knockout mice.
Girard E; Bernard V; Minic J; Chatonnet A; Krejci E; Molgó J
Life Sci; 2007 May; 80(24-25):2380-5. PubMed ID: 17467011
[TBL] [Abstract][Full Text] [Related]
15. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
16. Cholinesterase inhibitors: new roles and therapeutic alternatives.
Giacobini E
Pharmacol Res; 2004 Oct; 50(4):433-40. PubMed ID: 15304240
[TBL] [Abstract][Full Text] [Related]
17. The interactions of azure B, a metabolite of methylene blue, with acetylcholinesterase and butyrylcholinesterase.
Petzer A; Harvey BH; Petzer JP
Toxicol Appl Pharmacol; 2014 Feb; 274(3):488-93. PubMed ID: 24161345
[TBL] [Abstract][Full Text] [Related]
18. Cholinesterase inhibitors proposed for treating dementia in Alzheimer's disease: selectivity toward human brain acetylcholinesterase compared with butyrylcholinesterase.
Pacheco G; Palacios-Esquivel R; Moss DE
J Pharmacol Exp Ther; 1995 Aug; 274(2):767-70. PubMed ID: 7636741
[TBL] [Abstract][Full Text] [Related]
19. Effect of distigmine bromide on the central cholinergic system.
Nakayama K; Katsu H; Kitazumi K
J Psychopharmacol; 2009 Mar; 23(2):190-3. PubMed ID: 18515453
[TBL] [Abstract][Full Text] [Related]
20. Prolonged treatment with donepezil increases acetylcholinesterase expression in the central nervous system.
Zivin M; Pregelj P
Psychiatr Danub; 2008 Jun; 20(2):168-73. PubMed ID: 18587286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]